Roth Capital Partners, LLC
888 San Clemente Drive
Newport Beach, CA 92660
June 17, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
|
Re: |
Moleculin Biotech, Inc. |
|
Registration Statement on Form S-1 (Registration No. 333-287727) |
|
Concurrence in Acceleration Request |
Ladies and Gentlemen:
Roth Capital Partners, LLC (“Roth”), as placement agent for the referenced offering, hereby concurs in the request by Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on Wednesday, June 18, 2025, pursuant to Rule 461 under the Securities Act. Roth affirms that it is aware of its obligations under the Securities Act in connection with this offering.
[Signature Page Follows]
|
|
Very truly yours,
ROTH CAPITAL PARTNERS, LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Louis J. Ellis |
|
|
|
|
Name: Louis J. Ellis |
|
|
|
|
Title: Managing Director, Equity Capital Markets |
|